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have a biologically plausible explanation for why these
relationships would differ in women as compared with
men. The issues of a possible responder bias also need to
be evaluated.
Excess weight, particularly visceral, is known to pro-
duce a ‘pro-inﬂammatory’ state,4 and this may be relevant,
especially if one accepts that low grade inﬂammation is an
aetiological factor in functional GI disease.5 The authors
are to be congratulated for examining this issue in a large
dataset to highlight this association, but I would also
encourage them to review their available wealth of data
(on diet, exercise, menopausal status, etc.), to dissect out
any further clues which may help inform further studies
in this ﬁeld.
Functional GI disorders cost individuals and societies
greatly, and efforts to review lifestyle, dietary, environ-
mental and behavioural triggers, or co-factors which may
be amenable to population level management scientiﬁ-
cally are to be encouraged.
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Hepatic venous outﬂow tract obstruction (HVOTO) is a
rare cause of liver disease that tends to present in young
adults with manifestations of portal hypertension.
Although >80% of western HVOTO patients have an
identiﬁable thrombophilic risk factor, most eastern
HVOTO patients have idiopathic HVOTO and are more
likely to present with both vena cava and hepatic vein
occlusion.1 Due to its low incidence worldwide, accurate
estimates of the incidence and risk factors for HCC
development in HVOTO are not well described.2, 3 In a
recent issue, Paul et al. report on the incidence of HCC
in 413 HVOTO patients managed at a single referral
centre in India over a 25-year time period.4 The
observed annual rate of HCC of only 0.35% per year is
markedly lower compared to other more common causes
of chronic liver disease (Table 1).5, 6 The authors
reported that all of the patients with HCC had evidence
of cirrhosis. In addition, vena cava occlusion and older
subject age were more common in the patients with
HCC compared to controls, but the small number of
HCC cases precluded a multivariate analysis. Interest-
ingly, serum AFP levels were increased in >80% at the
time of HCC diagnosis as noted in prior studies.3
Important inferences from this study include the much
lower annual incidence of HCC in this large cohort of
HVOTO patients (0.35%) compared to prior estimates
(2–50%) reported in a recent meta-analysis.7 Limitations
of this retrospective case–control study include the lack
of data on other established risk factors for HCC (i.e.
anti-HBc status, smoking, alcohol consumption) and the
potential for underreporting with only 17% of patients
followed up for 5 years. Furthermore, establishing a diag-
nosis of HCC using contrast enhanced cross-sectional
imaging criteria is particularly challenging in HVOTO
patients due to their tendency to form arterialised liver
nodules. The association between more extensive vena
cava involvement with an apparent increased risk of
HCC has been suggested in prior reports.7 However,
whether these vascular occlusion patterns simply increase
the risk of HCC via accelerated ﬁbrosis progression or
through other mechanisms remain unclear.
In summary, HVOTO patients with cirrhosis appear
to be at increased risk of developing HCC. Serum AFP
testing may prove particularly useful for HCC surveil-
lance in ‘high risk’ HVOTO patients as has recently been
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reported in subjects with ﬁbrotic congestive hepatopa-
thy.5 Additional prospective studies are now needed to
determine if simple clinical parameters such as duration
and type of HVOTO, subject age, and non-invasive esti-
mates of ﬁbrosis severity (i.e. magnetic resonance elas-
tography) can further help identify ‘high risk’ HVOTO
patients that may beneﬁt from HCC surveillance.8
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We thank Drs Parikh and Fontana for their comments
regarding the results of our study.1, 2 However, there are
certain aspects, raised by Drs Parikh and Fontana that
needs clariﬁcation.
We fully agree that the diagnosis of HCC in the back-
ground of HVOTO is extremely challenging and numer-
ous benign-enhancing nodules can mimic HCC.
However, we could conﬁdently diagnose all 16 HVOTO
–HCC patients by the EASL criteria.3 All patients had
associated features of cirrhosis on imaging. Liver masses
depicted typical arterial enhancement with washout in
Table 1 | Incidence and features of HCC in patients with chronic liver disease
Hepatitis C HBV NASH HVOTO
Congenital heart
disease
Annual incidence 3–5% (cirrhotic) 3–8% (cirrhotic) 1–2% 0.35% <1%
Established
risk factors
Cirrhosis and
advanced ﬁbrosis
Age, male gender
Cirrhosis and
advanced ﬁbrosis
Age, infection
duration Prolonged
high HBV DNA/eAg+
Cirrhosis and
advanced ﬁbrosis
Cirrhosis Cirrhosis
AFP utility
in screening
Low Sensitivity
Low PPV + false
positives
Low Sensitivity
Low PPV
Low sensitivity
Low PPV
Sensitive and
speciﬁc
Sensitive and
speciﬁc
Worldwide
disease burden
High (increasing) High (stable) High (increasing) Very low (stable) Low (increasing)
HCV, hepatitis C virus; HBV, hepatitis B virus; NASH, non-alcoholic steatohepatitis; HVOTO, hepatic venous outﬂow tract obstruc-
tion; AFP, alfa fetoprotein; PPV, positive predictive value.
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